Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy: a review - Wikidata - wikimedia - TriplyDB

Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy: a review

Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy: a review

http://www.wikidata.org/entity/Q37230970

about

Targeted radionuclide therapies for pancreatic cancer Treatment of advanced pancreatic carcinoma with 90Y-Clivatuzumab Tetraxetan: a phase I single-dose escalation trial.Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial.Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours.Inhibition of Neddylation Modification Sensitizes Pancreatic Cancer Cells to Gemcitabine.Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair.Insulin-like growth factor axis gene polymorphisms and clinical outcomes in pancreatic cancer.Enhanced breast cancer therapy with nsPEFs and low concentrations of gemcitabine.Targeting Neddylation pathways to inactivate cullin-RING ligases for anticancer therapy Aberrant glycogen synthase kinase 3β is involved in pancreatic cancer cell invasion and resistance to therapy.DNA-Dependent Protein Kinase As Molecular Target for Radiosensitization of Neuroblastoma Cells.Prospective study of cetuximab and gemcitabine in combination with radiation therapy: feasibility and efficacy in locally advanced pancreatic head cancer Aberrant glycogen synthase kinase 3β in the development of pancreatic cancer.Gemcitabine-Based Chemoradiation in the Treatment of Locally Advanced Head and Neck Cancer: Systematic Review of Literature and Meta-Analysis.Neoadjuvant cetuximab, twice-weekly gemcitabine, and intensity-modulated radiotherapy (IMRT) in patients with pancreatic adenocarcinoma.Metabolic disorder, inflammation, and deregulated molecular pathways converging in pancreatic cancer development: implications for new therapeutic strategies.Profiling ribonucleotide and deoxyribonucleotide pools perturbed by gemcitabine in human non-small cell lung cancer cells.Role of cell cycle perturbations in the combination therapy of chemotherapeutic agents and radiation.Motexafin gadolinium: a promising radiation sensitizer in brain metastasis.DNA synthesis inhibitors for the treatment of gastrointestinal cancer.The radiosensitizing effect of fluorocyclopentenyl-cytosine (RX-3117) in ovarian and lung cancer cell lines.A ruthenium polypyridyl intercalator stalls DNA replication forks, radiosensitizes human cancer cells and is enhanced by Chk1 inhibition.Motexafin gadolinium: a novel radiosensitizer for brain tumors.

P2860

Q26801364-250205DD-55FB-4C43-89DC-22FE639FEBAA Q33395088-8CEABFFD-0006-4826-A1BD-63BEDD9C5472 Q33401123-47334366-263E-4EF8-9ADD-E837335B22EB Q33409382-6A4BB933-3C80-4856-B7DF-24F91BEF9626 Q33714709-8C5F38DA-766F-4C28-B2F2-5E5D18DBD990 Q33926817-4B71C0B4-B4A9-4B81-B25A-175CA6091AF2 Q34023117-9D59C8BD-997E-4EC7-8E78-E5AC0AE3ABDB Q34402129-469A1D01-169C-44AE-B49E-1401699F0535 Q34563129-869E9BC4-08B5-4D3C-A0DB-263B68876B24 Q34585992-033BF656-981D-4E25-BE5C-9979668D7E4B Q35881648-C910985F-56DE-4F65-B0A0-542EC133EF95 Q36376503-3D4AF84E-D85D-4F6F-BFF0-C6CE91224859 Q36450022-F10662EE-8FAD-4EAA-9A86-0C0448A61AF4 Q36452263-3F85CD33-8B37-4A46-9898-CF4E9D29D0AB Q36623214-5419D331-2503-4E67-B506-DFBBC922A52C Q37129787-2E15E93F-06B5-4893-B5B7-754965489470 Q37413849-D4595C1D-FB86-45AC-ABE5-5D683A385017 Q37797479-A0F5F9FC-FA79-49CC-B489-C891728C52DA Q38014582-E75C3CD3-8D64-494C-BD59-5A1A6F4BED03 Q38254307-03AEB9EB-D349-4FA5-86A8-538C47264D31 Q38728091-FF55B710-EF1A-46DD-83CA-E8B5B2608898 Q41207594-B1300DF6-EDB5-456A-8DD2-D2157D2296D5 Q48500564-BD2A86A3-E483-4D48-9D9F-12529585DAC4

P2860

Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy: a review

http://www.wikidata.org/entity/Q37230970

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

Improving gemcitabine-mediated ...... rly targeted therapy: a review

@en

Improving gemcitabine-mediated ...... ly targeted therapy: a review.

@nl

type

label

Improving gemcitabine-mediated ...... rly targeted therapy: a review

@en

Improving gemcitabine-mediated ...... ly targeted therapy: a review.

@nl

prefLabel

Improving gemcitabine-mediated ...... rly targeted therapy: a review

@en

Improving gemcitabine-mediated ...... ly targeted therapy: a review.

@nl

P1433

Q37230970-C0C2AFA6-9AFE-41E5-AB06-D3CD3BB55046

P1476

Q37230970-C9784152-A777-4E6E-AC93-7B0D3127C486

P2093

Q37230970-09F92323-F299-41BE-899D-B09EC9C31C10

Q37230970-B777B7F7-4F52-45DB-9431-B09493D36864

Q37230970-CB11C12A-DBFA-4397-A12E-B1575AFF1104

Q37230970-D0FC161E-9FE8-4114-A5A7-C817A690A746

P2860

Q37230970-01A3C4A3-402A-4DC4-98E9-FAE22AE82091

Q37230970-029ECB0A-415D-4299-BBC9-8E7F4157BCD0

Q37230970-032683F7-663E-45F2-99B1-D49DCEA5E378

Q37230970-0897C6BC-0CBF-4831-94AD-96799D015E0E

Q37230970-0B1CB426-9DF4-48D8-BFD7-71174A0FFA59

Q37230970-12BCF70F-5B28-4B11-94F4-A23AB403C09A

Q37230970-1A5C52AA-5067-4DD8-B8FC-5E6720DE8B65

Q37230970-1B234577-7AA0-4C50-8FBE-1E851564F685

Q37230970-1B3A6211-690E-4EDB-BCCA-7431D9D563B3

Q37230970-27EE6FFB-1056-491D-BA0E-9CF0E3007FD2

P304

Q37230970-3F4D80C6-5AD8-4E6A-85A8-DAD9203E1B27

P31

Q37230970-3AB0DF2A-3015-489A-A565-6C1DDF048E8E

P356

Q37230970-4E3D8325-F3AC-458A-A4E8-9F1AB1DD206A

P407

Q37230970-6E9613E2-3F8B-4E67-825A-0EF1072DB741

P433

Q37230970-94264E2E-82E7-4E5B-BD17-ED657DFCAAF2

P478

Q37230970-26E7334F-5A02-4747-9A9C-2EF0657B358F

P577

Q37230970-9C39AB84-A8A5-4E62-98F5-159AF74FF8EA

P698

Q37230970-5815016F-B778-4B74-85A4-D8FFC5E433C3

P932

Q37230970-F8F14FF5-E33F-41F0-864E-ADF3E61E1FF3

P356

1078-0432.CCR-08-1032

P1433

Clinical Cancer Research

P1476

Improving gemcitabine-mediated ...... rly targeted therapy: a review

@en

P2093

Jonathan Maybaum

http://www.w3.org/2001/XMLSchema#string

Leslie A Parsels

http://www.w3.org/2001/XMLSchema#string

Meredith A Morgan

http://www.w3.org/2001/XMLSchema#string

Theodore S Lawrence

http://www.w3.org/2001/XMLSchema#string

P2860

Linkage of ATM to cell cycle regulation by the Chk2 protein kinase

Survival of cancer cells is maintained by EGFR independent of its kinase activity

ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1

Synthesis and structure-activity relationships of soluble 8-substituted 4-(2-chlorophenyl)-9-hydroxypyrrolo[3,4-c]carbazole-1,3(2H,6H)-diones as inhibitors of the Wee1 and Chk1 checkpoint kinases

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine

Rapid destruction of human Cdc25A in response to DNA damage

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

P304

6744-6750

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-08-1032

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2008-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18980967

http://www.w3.org/2001/XMLSchema#string

P932

2697824

http://www.w3.org/2001/XMLSchema#string